Human papilloma virus (HPV) causes around 70% of head and neck cancers in the United States, making it the most common cancer ...

Maina Modu, an immunization officer in Nigeria’s northeastern Borno state, lost his wife, Hauwa, to cervical cancer in 2011.

The Head and Neck Cancer Drugs/Therapeutics Market is experiencing substantial growth, valued at USD 4.2 Billion in 2024 and ...

After decades of decline, rates of cervical cancer within Canada have plateaued, according to the Canadian Cancer Society — a ...

Link to the article in Clinical Cancer Research.] The study utilized Droplet's LymphDetect (TM) liquid biopsy assay for HPV-independent head & neck cancer. Results from two cohorts (initial n = 36, ...

Barbara Burtness, MD highlights key news in head and neck cancer from ESMO 2025, including CAMORAL, ASPEN-03 & -04, OrigAMI-4 & -05 results.

The oropharyngeal cancer market is anticipated to grow during the forecast period (2025--2034), driven by the launch of emerging therapies such as PDS Biotechnology's Versamune HPV, Inovio ...

A nanoparticle vaccine designed to fight cancers induced by human papillomavirus (HPV) eradicated tumors in an animal model ...

Cannabis use poses cancer risks beyond just your lungs — including oral cancer and other cancers involving the mouth, voice ...

A nanoparticle vaccine designed to fight cancers induced by human papillomavirus (HPV) eradicated tumors in an animal model ...

Get key insights from PDS Biotech’s Q3 2025 earnings call, including regulatory updates for PDS0101 in HPV16+ cancer and financial highlights.

Researchers from Rutgers Cancer Institute, New Jersey's only National Cancer Institute (NCI) - designated Comprehensive Cancer Center, and RWJBarnabas Health, along with colleagues from the National ...